Sophie Vinay-Postel

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.

Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 28, 2026

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Journal: Cancer research communications

Published: March 25, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Journal: Cancer research communications

Published: March 25, 2026

Translational aspects of Desmoplastic small round cell tumor (DSRCT): An expert consensus paper from the OCTOPUS group.

Translational aspects of Desmoplastic small round cell tumor (DSRCT): An expert consensus paper from the OCTOPUS group.

Journal: Critical reviews in oncology/hematology

Published: January 30, 2026

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 02, 2026

Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations.

Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 21, 2025

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 19, 2025

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Journal: British journal of cancer

Published: September 15, 2025

Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine.

Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine.

Journal: NPJ breast cancer

Published: July 18, 2025

Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.

Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.

Journal: Cancer communications (London, England)

Published: April 05, 2025

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Journal: Molecular oncology

Published: February 27, 2025

Showing 1-12 of 125

Last Updated: 09/26/2026